A California federal judge has let the Federal Trade Commission drop its federal court challenge to biotech giant Illumina's planned purchase of a cancer detection company but kept the door open to a future suit, despite the firms' warning that doing so would let the commission kill the deal later by reviving its challenge as the merger's termination date draws near.